## Drug Summary
Sertraline, also known commercially as Lustral, is classified under the selective serotonin reuptake inhibitors (SSRIs), a group that also includes citalopram and fluoxetine. SSRIs are commonly prescribed for managing major depressive disorders, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, premenstrual dysphoric disorder, and social anxiety disorder, and have a range of off-label uses such as generalized anxiety disorder and migraine prophylaxis. Like other SSRIs, sertraline primarily functions through the inhibition of serotonin (5-HT) reuptake, enhancing serotonergic activity in the central nervous system. Furthermore, it has a favorable safety and tolerability profile compared to tricyclic antidepressants, showing less sedative and cardiovascular side effects. However, sertraline may require several weeks of administration before showing beneficial effects on mood and anxiety symptoms. It is absorbed orally with a bioavailability above 44%, reaches peak plasma concentrations within about 4.5 to 8.4 hours, and is extensively metabolized in the liver primarily by CYP3A4 and CYP2B6, among others.

## Drug Targets, Enzymes, Transporters, and Carriers
Sertraline targets multiple transporters, most notably the sodium-dependent serotonin transporter (SLC6A4), crucial for its antidepressant and anxiolytic effects. Other targets include the sodium-dependent dopamine transporter (SLC6A3) and noradrenaline transporter (SLC6A2), which contribute to its complex psychotropic profile. It exhibits affinity for sigma receptors (SIGMAR1 and PGRMC1), potentially influencing its therapeutic effects and side activity profiles. Metabolism of sertraline involves several cytochrome P450 enzymes; predominantly CYP3A4 and CYP2B6, with significant roles also played by CYP2C19 and CYP2D6. The drug is a substrate for the transporter P-glycoprotein 1 (ABCB1) and is carried by serum albumin (ALB), which may affect its distribution and elimination. 

## Pharmacogenetics
Pharmacogenetic factors significantly influence the metabolism of sertraline, particularly involving polymorphisms in CYP2C19. Allelic variations such as rs4244285 and rs4986893 in the CYP2C19 gene are associated with poor metabolism of sertraline, which can affect drug levels and contribute to variability in patient responses and potential side effects. Poor metabolizers may experience higher plasma concentrations of sertraline, leading to an increased risk of adverse effects or toxicity. Adjustments in dosage or alternative therapies might be considered based on the CYP2C19 genotype. Additional research and clinical data could further clarify the impact of genetic variations in transporter and other metabolic enzymes like CYP2D6 on sertralineâ€™s pharmacokinetics and pharmacodynamics.